Echo IQ (EIQ) Piper Sandler 37th Annual Healthcare Conference summary

Business overview and technology

• Focuses on early, accurate diagnosis of heart disease, especially aortic stenosis and heart failure, using AI-driven analysis of echocardiogram measurements rather than images.

• AI model creates a unique risk fingerprint for each patient, comparing it to over 1 million echocardiograms for real-time disease presence and phenotypic risk scoring.

• Technology identifies severe cases, especially in women who present differently, and integrates seamlessly into hospital workflows via cloud-based SaaS.

• Achieves near-perfect diagnostic accuracy (AUC 0.986) and is FDA-cleared for aortic stenosis, with ongoing hospital integrations.

Clinical validation and market impact

• Clinical studies across multiple geographies show up to 100% effectiveness in diagnosing severe aortic stenosis, with FDA clearance and real-world evidence.

• Heart failure solution demonstrated 86% accuracy with AI alone and 97% when combined with physician expertise; validation with Mayo Clinic showed 99.5% sensitivity and 91% specificity.

• Heart failure model to be submitted to FDA imminently, targeting clearance by early 2026.

• Large, growing market driven by aging population and comorbidities like obesity and hypertension.

Commercial strategy and financials

• Three strategic pillars: hospital integration, reimbursement/revenue, and pipeline platform expansion.

• Integrating with major U.S. hospitals, including Beth Israel Deaconess Medical Center, and targeting both large and small institutions.

• Current reimbursement: $150 for aortic stenosis model, $250–$300 for heart failure, with ongoing efforts for dedicated CPT codes.

• Raised $17.5 million, with $15 million in the bank and a $600,000 monthly burn rate; considering a U.S. IPO.